ArticlePloS one2026
Cost-effectiveness analysis of computer aided detection for tuberculosis in Ghana: A decision-analytic modeling study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe financial sustainability of universal molecular testing for tuberculosis (TB) remains a critical challenge in high-burden settings. In Ghana, the national program utilizes GeneXpert MTB/RIF for confirmation, yet the high unit cost necessitates efficient triage tools. This study evaluates the cost-effectiveness of Computer-Aided Detection (CAD) based triage compared to the standard of care in Ghana.
methodsThis is a prospective cross-sectional diagnostic accuracy study, with an embedded decision-analytic economic evaluation, using primary data from 701 symptomatic outpatients across 23 facilities in Ghana. The cost-effectiveness analysis compared the vendor-recommended threshold of 51 with locally calibrated CAD scores of 56 (weighted Youden) and 68 (standard Youden). These were evaluated against the current Standard of Care (symptom screening and human-read chest X-ray). Health outcomes were measured in Quality-Adjusted Life Years (QALYs) lost, applying a severe morbidity penalty to missed TB cases (False Negatives) to account for prolonged suffering. The primary outcome was the Incremental Cost-Effectiveness Ratio (ICER). Analysis was conducted with R version 4.3.
resultsThe CAD-based triage at the weighted Youden threshold of 56 was identified as the optimal clinical strategy, being both more effective and less expensive than the current Standard of Care (SoC). The total health system pathway cost for the CAD-56 strategy and SoC was US$23,449.01 and US$33,239.09, respectively. Threshold of CAD-56 instead of the SoC saved the health system US$9,790.08 on 701 individuals screened and yielding an incremental health gain of 10.08 Quality-Adjusted Life Years (QALYs).
conclusionImplementing locally calibrated CAD4TB version 7 at an optimized threshold of 56 as a gatekeeper for molecular testing would be a dominant economic strategy for TB control in Ghana. The findings provide a preliminary evidence for further assessment with nationwide data before national rollout of AI-based triage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.